{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:30:34Z","timestamp":1794346234336,"version":"4.9.0"},"reference-count":167,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease with no approved therapies. The ursodeoxycholic acid (UDCA) has been widely used, although there is no evidence that the use of UDCA delays the time to liver transplant or increases survival. Several candidate drugs are currently being developed. The largest group of these new agents is represented by FXR agonists, including obeticholic acid, cilofexor, and tropifexor. Other agents that target bile acid metabolism are ASTB\/IBAP inhibitors and fibroblasts growth factor (FGF)19 analogues. Cholangiocytes, the epithelial bile duct cells, play a role in PSC development. Recent studies have revealed that these cells undergo a downregulation of GPBAR1 (TGR5), a bile acid receptor involved in bicarbonate secretion and immune regulation. Additional agents under evaluation are PPARs (elafibranor and seladelpar), anti-itching agents such as MAS-related G-protein\u2013coupled receptors antagonists, and anti-fibrotic and immunosuppressive agents. Drugs targeting gut bacteria and bile acid pathways are also under investigation, given the strong link between PSC and gut microbiota.<\/jats:p>","DOI":"10.3390\/cells13191650","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T03:26:36Z","timestamp":1728012396000},"page":"1650","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-4222","authenticated-orcid":false,"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Urbani","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7125-8963","authenticated-orcid":false,"given":"Cristina","family":"Di Giorgio","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-6896","authenticated-orcid":false,"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[{"name":"Dipartimento di Medicina e Chirurgia, Universit\u00e0 di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[{"name":"SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis\u2014A comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"Wang","year":"2018","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"Vesterhus","year":"2015","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/bmb\/ldv019","article-title":"Primary sclerosing cholangitis: A clinical update","volume":"114","author":"Williamson","year":"2015","journal-title":"Br. Med. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2017.06.027","article-title":"Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis","volume":"67","author":"Trivedi","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate with Course of Primary Sclerosing Cholangitis","volume":"152","author":"Trivedi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial","volume":"160","author":"Bolier","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12072-020-10118-x","article-title":"Management of primary sclerosing cholangitis and its complications: An algorithmic approach","volume":"15","author":"Beuers","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.3748\/wjg.14.3781","article-title":"Autoantibodies in primary sclerosing cholangitis","volume":"14","author":"Hov","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1055\/s-0032-1325677","article-title":"Risk factors for complications of ERCP in primary sclerosing cholangitis","volume":"44","author":"Ismail","year":"2012","journal-title":"Endoscopy"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2017.12.002","article-title":"Primary sclerosing cholangitis: A review and update","volume":"1","author":"Tabibian","year":"2017","journal-title":"Liver Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2013.06.052","article-title":"Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management","volume":"145","author":"Eaton","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2020.05.047","article-title":"Blocking integrin \u03b14\u03b27-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis","volume":"73","author":"Rai","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gupta, B., Rai, R.P., Pal, P.B., Rossmiller, D., Chaudhary, S., Chiaro, A., Seaman, S., Singhi, A.D., Liu, S., and Monga, S.P. (2024). Selective Targeting of \u03b14\u03b27\/MAdCAM-1 Axis Suppresses Fibrosis Progression by Reducing Proinflammatory T Cell Recruitment to the Liver. Cells, 13.","DOI":"10.3390\/cells13090756"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.bbadis.2017.08.020","article-title":"Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma","volume":"1864","author":"Chung","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng.3745","article-title":"Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease","volume":"49","author":"Ji","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2012.03.031","article-title":"Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci","volume":"57","author":"Folseraas","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e0461","DOI":"10.1097\/HC9.0000000000000461","article-title":"Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis","volume":"8","author":"Grimsrud","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.728","article-title":"Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci","volume":"43","author":"Melum","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng.2616","article-title":"Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis","volume":"45","author":"Liu","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/ng.3760","article-title":"Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease","volume":"49","author":"Moutsianas","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcmgh.2015.05.005","article-title":"Functional and structural features of cholangiocytes in health and disease","volume":"1","author":"Maroni","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","article-title":"Cholangiocyte pathobiology","volume":"16","author":"Banales","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.cellbio.22.010305.104219","article-title":"Tight junctions and cell polarity","volume":"22","author":"Shin","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MOG.0b013e3280b079fb","article-title":"Cholangiocyte biology","volume":"23","author":"Bogert","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbadis.2017.07.024","article-title":"Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology","volume":"1864","author":"Pinto","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2002-34501","article-title":"Functional heterogeneity of cholangiocytes","volume":"22","author":"Marzioni","year":"2002","journal-title":"Semin. Liver Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0168-8278(96)80014-6","article-title":"A morphometric study of the epithelium lining the rat intrahepatic biliary tree","volume":"24","author":"Benedetti","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.3748\/wjg.v12.i22.3523","article-title":"Heterogeneity of the intrahepatic biliary epithelium","volume":"12","author":"Glaser","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cphy.c120019","article-title":"Physiology of cholangiocytes","volume":"3","author":"Tabibian","year":"2013","journal-title":"Compr. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature23015","article-title":"Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration","volume":"547","author":"Raven","year":"2017","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1038\/s41467-021-26764-0","article-title":"Generation of functional ciliated cholangiocytes from human pluripotent stem cells","volume":"12","author":"Ogawa","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2006.07.003","article-title":"Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling","volume":"131","author":"Masyuk","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_37","first-page":"2007","article-title":"Cholangiocyte primary cilia in liver health and disease","volume":"237","author":"Masyuk","year":"2008","journal-title":"Dev. Dyn. Off. Publ. Am. Assoc. Anat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00424-021-02622-2","article-title":"The bile acid-sensitive ion channel (BASIC) mediates bile acid-dependent currents in bile duct epithelial cells","volume":"473","author":"Wiegreffe","year":"2021","journal-title":"Pfl\u00fcgers Arch.-Eur. J. Physiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1053\/j.gastro.2004.08.006","article-title":"The cholangiopathies: Disorders of biliary epithelia","volume":"127","author":"Lazaridis","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing Cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mayocp.2015.03.017","article-title":"The Cholangiopathies","volume":"90","author":"Lazaridis","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcmgh.2022.11.006","article-title":"Pathophysiological Roles of Ductular Reaction in Liver Inflammation and Hepatic Fibrogenesis","volume":"15","author":"Sato","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_43","first-page":"G1077","article-title":"Advances in cholangiocyte immunobiology","volume":"303","author":"Syal","year":"2012","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1038\/s41467-022-32575-8","article-title":"Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/hep.30472","article-title":"Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis","volume":"69","author":"Coll","year":"2019","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.30150","article-title":"Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances","volume":"69","author":"Sato","year":"2019","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.gastro.2013.11.034","article-title":"Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion","volume":"146","author":"Williams","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/labinvest.2014.94","article-title":"Characterization of cultured cholangiocytes isolated from livers of patients with primary sclerosing cholangitis","volume":"94","author":"Tabibian","year":"2014","journal-title":"Lab. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/hep.26993","article-title":"Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis","volume":"59","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00281-022-00909-9","article-title":"Cellular senescence in the cholangiopathies: A driver of immunopathology and a novel therapeutic target","volume":"44","author":"Trussoni","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: The dark side of tumor suppression","volume":"5","author":"Desprez","year":"2010","journal-title":"Annu. Rev. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/hep.22348","article-title":"Telomere shortening in the damaged small bile ducts in primary biliary cirrhosis reflects ongoing cellular senescence","volume":"48","author":"Sasaki","year":"2008","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e170320","DOI":"10.1172\/jci.insight.170320","article-title":"Telomere dysfunction promotes cholangiocyte senescence and biliary fibrosis in primary sclerosing cholangitis","volume":"8","author":"Anwar","year":"2023","journal-title":"JCI Insight"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls","volume":"163","author":"Fisher","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: Unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.21792","article-title":"Transforming growth factor-\u03b2 and substrate stiffness regulate portal fibroblast activation in culture","volume":"46","author":"Li","year":"2007","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hep.31140","article-title":"Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients with Primary Sclerosing Cholangitis (PSC)","volume":"72","author":"Kunzmann","year":"2020","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3727\/105221618X15156018385515","article-title":"Bile Acid Metabolism in Liver Pathobiology","volume":"18","author":"Chiang","year":"2018","journal-title":"Gene Expr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: Regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10545-010-9259-3","article-title":"Disorders of bile acid synthesis","volume":"34","author":"Clayton","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: Molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41564-023-01337-7","article-title":"Bile salt hydrolases shape the bile acid landscape and restrict Clostridioides difficile growth in the murine gut","volume":"8","author":"Foley","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41586-023-06990-w","article-title":"Bile salt hydrolase catalyses formation of amine-conjugated bile acids","volume":"626","author":"Rimal","year":"2024","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"112997","DOI":"10.1016\/j.celrep.2023.112997","article-title":"Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancer progression","volume":"42","author":"Fu","year":"2023","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.cell.2024.02.019","article-title":"The underappreciated diversity of bile acid modifications","volume":"187","author":"Mohanty","year":"2024","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.plipres.2024.101291","article-title":"Immunology of bile acids regulated receptors","volume":"95","author":"Fiorucci","year":"2024","journal-title":"Prog. Lipid Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","article-title":"Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis","volume":"75","author":"Reich","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.bbadis.2017.08.021","article-title":"Bile acid receptors in the biliary tree: TGR5 in physiology and disease","volume":"1864","author":"Deutschmann","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1021\/jm500889f","article-title":"Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1)","volume":"57","author":"Sepe","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Cipriani, S., Renga, B., D\u2019Amore, C., Simonetti, M., De Tursi, A.A.A., Carino, A., Monti, M.C.C., Sepe, V., Zampella, A., and Fiorucci, S. (2015). Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129866"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hep.24681","article-title":"Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes","volume":"55","author":"Studer","year":"2012","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Di Giorgio, C., Bellini, R., Lupia, A., Massa, C., Bordoni, M., Marchian\u00f2, S., Rosselli, R., Sepe, V., Rapacciuolo, P., and Moraca, F. (2023). Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1140730"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Di Giorgio, C., Morretta, E., Lupia, A., Bellini, R., Massa, C., Urbani, G., Bordoni, M., Marchian\u00f2, S., Lachi, G., and Rapacciuolo, P. (2024). Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis. Biochem. Pharmacol., 223.","DOI":"10.1016\/j.bcp.2024.116134"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.soard.2020.08.028","article-title":"Recent advances in the mechanisms underlying the beneficial effects of bariatric and metabolic surgery","volume":"17","author":"Xu","year":"2020","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","article-title":"Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis","volume":"25","author":"Hao","year":"2017","journal-title":"Cell Metab."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/gast.2001.25503","article-title":"The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp","volume":"121","author":"Denson","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/164_2019_235","article-title":"The Enterokine Fibroblast Growth Factor 15\/19 in Bile Acid Metabolism","volume":"Volume 256","author":"Cariello","year":"2019","journal-title":"Handbook of Experimental Pharmacology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"G1124","DOI":"10.1152\/ajpgi.00539.2005","article-title":"Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents","volume":"290","author":"Boyer","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.22627","article-title":"Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression","volume":"49","author":"Song","year":"2009","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28541","article-title":"Deregulated methionine adenosyltransferase \u03b11, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans","volume":"64","author":"Yang","year":"2016","journal-title":"Hepatology"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Milkiewicz, M., Klak, M., Kempinska-Podhorodecka, A., Wiechowska-Kozlowska, A., Urasinska, E., Blatkiewicz, M., Wunsch, E., Elias, E., and Milkiewicz, P. (2016). Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis. Sci. Rep., 6.","DOI":"10.1038\/srep39573"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbagrm.2011.01.008","article-title":"Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter","volume":"1809","author":"Renga","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1073\/pnas.0604772103","article-title":"Benefit of farnesoid X receptor inhibition in obstructive cholestasis","volume":"103","author":"Stedman","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Renga, B., Mencarelli, A., D\u2019Amore, C., Cipriani, S., D\u2019Auria, M.V.V., Sepe, V., Chini, M.G.G., Monti, M.C.C., Bifulco, G., and Zampella, A. (2012). Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030443"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.0907812106","article-title":"Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob\/ob mice","volume":"106","author":"Wu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jhep.2019.06.011","article-title":"Obeticholic acid may increase the risk of gallstone formation in susceptible patients","volume":"71","author":"Panzitt","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1021\/jo2023763","article-title":"Quantitative NMR-derived interproton distances combined with quantum mechanical calculations of 13C chemical shifts in the stereochemical determination of conicasterol F, a nuclear receptor ligand from Theonella swinhoei","volume":"77","author":"Chini","year":"2012","journal-title":"J. Org. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Renga, B., Mencarelli, A., Cipriani, S., D\u2019Amore, C., Carino, A., Bruno, A., Francisci, D., Zampella, A., Distrutti, E., and Fiorucci, S. (2013). The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054472"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2010.08.022","article-title":"Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells","volume":"80","author":"Mencarelli","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yoshihara, A., Kawasaki, H., Masuno, H., Takada, K., Numoto, N., Ito, N., Hirata, N., Kanda, Y., Ishizawa, M., and Makishima, M. (2022). Lithocholic Acid Amides as Potent Vitamin D Receptor Agonists. Biomolecules, 12.","DOI":"10.3390\/biom12010130"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Biagioli, M., Marchian\u00f2, S., Carino, A., Di Giorgio, C., Santucci, L., Distrutti, E., and Fiorucci, S. (2021). Bile Acids Activated Receptors in Inflammatory Bowel Disease. Cells, 10.","DOI":"10.3390\/cells10061281"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-024-00914-3","article-title":"The changing metabolic landscape of bile acids\u2014Keys to metabolism and immune regulation","volume":"21","author":"Mohanty","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","article-title":"Microbial bile acid metabolites modulate gut ROR\u03b3(+) regulatory T cell homeostasis","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nm.4046","article-title":"Transient inhibition of ROR-\u03b3t therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells","volume":"22","author":"Withers","year":"2016","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1053\/j.gastro.2012.07.108","article-title":"T-helper 17 and interleukin-17-producing lymphoid tissue inducer-like cells make different contributions to colitis in mice","volume":"143","author":"Ono","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100561","DOI":"10.1016\/j.jhepr.2022.100561","article-title":"Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis","volume":"4","author":"Braadland","year":"2022","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jcmgh.2023.12.005","article-title":"Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts","volume":"17","author":"Schnabl","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2020.12.058","article-title":"Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis","volume":"160","author":"Kummen","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gutjnl-2021-326500","article-title":"Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC","volume":"72","author":"Awoniyi","year":"2023","journal-title":"Gut"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: Vancomycin or metronidazole in patients with primary sclerosing cholangitis\u2014A pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors Associated with Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.30085","article-title":"Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"ref_115","first-page":"2785","article-title":"Simple Magnetic Resonance Scores Associate with Outcomes of Patients with Primary Sclerosing Cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.29293","article-title":"Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group","volume":"66","author":"Schramm","year":"2017","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100595","DOI":"10.1016\/j.jhepr.2022.100595","article-title":"Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis","volume":"4","author":"Grigoriadis","year":"2022","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results with Insights on the Natural History of the Disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e2431108","DOI":"10.2214\/AJR.24.31108","article-title":"Association Between MR Elastography Liver Stiffness and Histologic Liver Fibrosis in Children and Young Adults with Autoimmune Liver Disease","volume":"223","author":"Dillman","year":"2024","journal-title":"AJR. Am. J. Roentgenol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: Pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/17474124.2018.1424538","article-title":"New therapies target the toxic consequences of cholestatic liver disease","volume":"12","author":"Jansen","year":"2018","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group","volume":"336","author":"Lindor","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/hep4.1251","article-title":"Gamma Glutamyltransferase Reduction Is Associated with Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis","volume":"2","author":"Deneau","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases","volume":"35","author":"Halilbasic","year":"2017","journal-title":"Dig. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000454853","article-title":"Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease","volume":"35","author":"Steinacher","year":"2017","journal-title":"Dig. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-Norursodeoxycholic acid reshapes immunometabolism in CD8(+) T cells and alleviates hepatic inflammation","volume":"75","author":"Zhu","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). The EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol., 67, 145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_134","first-page":"2076","article-title":"New Treatment Paradigms in Primary Biliary Cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2015.1045413","article-title":"Farnesoid X receptor modulators (2011\u20132014): A patent review","volume":"25","author":"Sepe","year":"2015","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor","volume":"103","author":"Inagaki","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic Messengers: Fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2018.11.061","article-title":"Small Heterodimer Partner and Fibroblast Growth Factor 19 Inhibit Expression of NPC1L1 in Mouse Intestine and Cholesterol Absorption","volume":"156","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"29069","DOI":"10.1074\/jbc.C700130200","article-title":"Co-receptor requirements for fibroblast growth factor-19 signaling","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"100917","DOI":"10.1016\/j.jhepr.2023.100917","article-title":"Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice","volume":"6","author":"Kunst","year":"2024","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","article-title":"FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2","volume":"79","author":"Xie","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_147","first-page":"695","article-title":"The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer","volume":"47","author":"Bellini","year":"2023","journal-title":"Cell. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Cipriani, S., Mencarelli, A., Chini, M.G.M.G.G.M.G.M.G.G., Distrutti, E., Renga, B., Bifulco, G., Baldelli, F., Donini, A., and Fiorucci, S. (2011). The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025637"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.1700183","article-title":"The Bile Acid Receptor GPBAR1 Regulates the M1\/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis","volume":"199","author":"Biagioli","year":"2017","journal-title":"J. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Hov, J.R., Keitel, V., Laerdahl, J.K., Spomer, L., Ellinghaus, E., ElSharawy, A., Melum, E., Boberg, K.M., Manke, T., and Balschun, T. (2010). Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012403"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e0153","DOI":"10.1097\/HC9.0000000000000153","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study","volume":"7","author":"Bowlus","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1007\/s10753-022-01713-1","article-title":"Fenofibrate Downregulates NF-\u03baB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis","volume":"45","author":"Gallucci","year":"2022","journal-title":"Inflammation"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Lefebvre, E., Moyle, G., Reshef, R., Richman, L.P., Thompson, M., Hong, F., Chou, H.L., Hashiguchi, T., Plato, C., and Poulin, D. (2016). Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study","volume":"5","author":"Eksteen","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/hep4.1926","article-title":"A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis","volume":"6","author":"Carey","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","article-title":"Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis","volume":"72","author":"Voskens","year":"2023","journal-title":"Gut"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/apt.17251","article-title":"Systematic review: Microbial manipulation as therapy for primary sclerosing cholangitis","volume":"57","author":"Bogatic","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: A Pilot Study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e44116","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that may mediate a component of cholestatic itch","volume":"8","author":"Meixiong","year":"2019","journal-title":"eLife"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e131712","DOI":"10.1172\/jci.insight.131712","article-title":"Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity","volume":"4","author":"Castro","year":"2019","journal-title":"JCI Insight"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbalip.2019.07.006","article-title":"Ursodeoxycholic acid is a GPBAR1 agonist and resets liver\/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH","volume":"1864","author":"Carino","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/19\/1650\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:10:19Z","timestamp":1760112619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/13\/19\/1650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":167,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cells13191650"],"URL":"https:\/\/doi.org\/10.3390\/cells13191650","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}